Mortal brain cancer of the man disappears after experimental drug treatment

A man with the deadliest form of brain cancer has no signs of illness after taking an experimental medication.

Ben Trotman was 40 years old when he was diagnosed in 2022 with a glioblastoma, the most aggressive cancer brain tumor. Patients generally live on average 15 months after diagnosis, and the rate of survival at five years is only 6.9%.

Trotman was returned to the National Hospital of Neurology and Neurosurgery of the University College London Hospitals (UCLH), where he was processed by the consultant as a medical oncologist UCLH, Dr Paul Mulholland, as detailed in a press release.

The mushroom of the curse of ancient “pharaoh” is promising to kill cancer cells

As the only person registered in a trial that finally closed its doors due to the lack of patients, Trotman received a medication called ipilimab, a targeted immunotherapy treatment.

Ipilimumab is an antibody that binds to a protein on immune cells (T cells). It prevents cancer cells from removing the immune system so that it can then attack and kill cancer, according to the National Cancer Institute.

Ben Trotman, a photo with his wife Emily and his daughter Mabel, were 40 years old when he was diagnosed in 2022 with glioblastoma, the most aggressive cancer brain tumor. (Marie Mangan via University College London)

Trotman also received radiation and chemotherapy.

More than two years later, his quarterly analyzes show no sign of cancer.

“It is very unusual to have a clear scan with the glioblastoma, especially when it has not undergone the follow -up surgery which had been planned to remove the entire tumor which was initially visible on the analyzes,” said its oncologist, Mulholland, in the press release.

“We estimated that we had a lucky break in a differently devastating situation.”

“We hope that immunotherapy and follow -up treatment that Ben has had his tumor from a distance – and it is so far that we are delighted to see.”

Two months after receiving ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter, Mabel.

Two months after receiving ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter, Mabel. (Ben and Emily Trotman via University College London)

“Obtaining this diagnosis was the most traumatic experience – we attacked that Ben had apparently passed in perfect health in months to live,” Emily Trotman said in the press release.

Click here to obtain the Fox News app

“If we had not met Dr. Mulholland, it would have been for us. We estimated that we had a lucky break in a situation otherwise devastating.”

Ben Trotman added: “We obviously do not know what the future has in store for us, but having had the treatment of immunotherapy and obtaining these encouraging digitization results gave a little hope).”

Dr. Paul Mulholland, on the left, is represented with Dame Siobhain McDonagh, on the right, who collected funds to support a new test for the experimental medication on glioblastoma. (Marie Mangan via University College London)

“We focus on the reconstruction of the life we thought we had lost and like to be parents.”

Mulholland and his team have now opened another clinical trial for patients who were recently diagnosed with glioblastoma.

Click here to register for our Health Newsletter

Sixteen patients will be recruited for the test, sponsored by the UCL.

Treatment will be administered at the NIHR UCLH Clinical Research Center and the National Hospital of Neurology and Neurosurgery, according to the press release.

Patients will receive ipilimumab before proceeding with standard treatments that may include surgery, radiotherapy and chemotherapy.

Patients with glioblastoma generally live on average 15 months after diagnosis, and the rate of survival at five years is only 6.9%. (istock)

“The crucial element of this test is that patients will have their immune system stimulated by the drug before having another treatment, when they are in good shape and good enough to tolerate immunotherapy,” Mulholland said in the press release.

The Win -Glio trial – nicknamed “Margaret’s Trial” – is funded by the efforts of Dame Siobhain McDonagh, sister of Margaret McDonagh, a London woman who died of a glioblastoma in 2023 and was treated by Mulholland.

For more health items, visit www.foxnews.com/health

Ben Trotman said he was “delighted” that the new trial is advancing with the same immunotherapy medication he had received.

“It will give people a little diagnosed with glioblastoma a little hope.”